Want to see AU:LGP full AI Analyst Report?
LGP Stock Chart & Stats
AU$0.10
<AU$0.01(1.67%)
At close: 4:00 PM EST
AU$0.10
<AU$0.01(1.67%)
Day’s Range― - ―
52-Week RangeAU$0.06 - AU$0.15
Previous CloseN/A
Volume21.69K
Average Volume (3M)234.87K
Market Cap
AU$61.27M
Enterprise ValueAU$28.30M
Total Cash (Recent Filing)AU$1.42M
Total Debt (Recent Filing)AU$4.69M
Price to Earnings (P/E)―
Beta0.98
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding827,978,700
10 Day Avg. Volume223,605
30 Day Avg. Volume234,865
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)0.36
Price to Sales (P/S)0.70
P/FCF Ratio-37.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside50.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow absolute debt versus a sizeable equity base provides durable financial flexibility. This reduces solvency risk, enables investment in cultivation/manufacturing capacity or regulatory compliance, and lowers refinancing pressure during cyclical revenue swings, supporting multi‑month resilience.
Vertical Integration Across Value ChainOwning cultivation, processing and manufacturing secures supply, quality and regulatory compliance advantages critical in medical cannabis. Vertical integration supports margin preservation, consistent product specs for GMP markets, and scaleable export capabilities that sustain growth over several months.
Multi-year Revenue ScaleThe company has demonstrated capacity to expand sales substantially over several years, indicating product adoption and distribution reach in regulated markets. That historical scaling supports realistic paths to margin recovery and volume leverage if demand stabilizes.
Bears Say
Recent Revenue DeclineAn 11.9% revenue drop in the latest year signals structural demand, pricing or mix challenges. If sustained, declines can erode operating leverage, reduce capacity utilization in cultivation/manufacturing, and pressure margins and investment plans over the next several months.
Inconsistent ProfitabilityVolatile earnings and a return to net loss reduce the company's ability to self-finance growth and increase uncertainty for long-term planning. Intermittent profitability makes sustaining R&D, quality systems and export initiatives harder without external capital over a multi‑month horizon.
Negative Free Cash FlowPersisting negative free cash flow, even after improvement, means the business still does not reliably fund investments from operations. Continued FCF shortfalls increase reliance on external funding and constrain capacity investments or margin-improvement programs over the next 2–6 months.
Little Green Pharma Ltd. News
LGP FAQ
What was Little Green Pharma Ltd.’s price range in the past 12 months?
Little Green Pharma Ltd. lowest share price was AU$0.06 and its highest was AU$0.14 in the past 12 months.
What is Little Green Pharma Ltd.’s market cap?
Little Green Pharma Ltd.’s market cap is AU$61.27M.
When is Little Green Pharma Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Little Green Pharma Ltd.’s earnings last quarter?
Currently, no data Available
Is Little Green Pharma Ltd. overvalued?
According to Wall Street analysts Little Green Pharma Ltd.’s price is currently Undervalued.
Does Little Green Pharma Ltd. pay dividends?
Little Green Pharma Ltd. does not currently pay dividends.
What is Little Green Pharma Ltd.’s EPS estimate?
Little Green Pharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Little Green Pharma Ltd. have?
Little Green Pharma Ltd. has 827,978,700 shares outstanding.
What happened to Little Green Pharma Ltd.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Little Green Pharma Ltd.?
Currently, no hedge funds are holding shares in AU:LGP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Little Green Pharma Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.15 (50.00% Upside)
AU$0.15 (50.00% Upside)
Blogger Sentiment
Bullish
AU:LGP Sentiment 100%
Sector Average ―
Sector Average ―
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.73%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-2.46%
Trailing 12-Months
Company Description
Little Green Pharma Ltd.
Little Green Pharma Ltd, established in 2016 and based in West Perth, Australia, specializes in the worldwide cultivation, manufacturing, and distribution of medicinal cannabis products. Its extensive product range encompasses cannabis flower medicines, various cannabis extracts, tinctures, and active pharmaceutical ingredients (APIs), serving markets both within Australia and internationally.
LGP Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(50.00% Upside)
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―